This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' CEO Chats: Edwards Lifesciences and Galena Biopharma

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Michael Mussallem, chairman and CEO of Edwards Lifesciences (EW - Get Report), and Dr. Mark Ahn, president and CEO of Galena Biopharma (GALE), representing both the big and small sides of health care in America.

These are excerpts from Cramer's 'Mad Money' Recap, originally published on Jan. 15 and Jan. 16, 2014.

Executive Decision: Michael Mussallem

For his second "Executive Decision" segment, Cramer spoke with Michael Mussallem, chairman and CEO of Edwards Lifesciences, one of last year's laggards that is now up 7% so far in 2014.

Must Read: Jim Cramer's 'Mad Money' CEO Chats: Regeneron and Alkermes

Mussallem commented on his company's recent legal win against Medtronic (MDT) for patent infringement. He called the decision a big win for his team as it's the second time a jury have found in the company's favor.

Mussallem continued that Edwards has always been an innovator, inventing in the technology that allows heart value implants without the need for open-heart surgery.

When asked why the company lowered expectations for Wall Street analysts, Mussallem said there was never a question if competition was coming, only when, and now that its here, it's only prudent to be realistic.

That said, Mussallem touted his company's new "Sapien 3" technology as the next generation of treatments, something the competition will not be able to mimic for quite some time.

Cramer said that Edwards has a lot of great technology and last year's laggards may just be this year's big winners.

Executive Decision: Mark Ahn

For his "Executive Decision" segment, Cramer spoke with Dr. Mark Ahn, president and CEO of Galena Biopharma, a smaller, speculative biotech company that's showing a lot of promise with its NeuVax anti-cancer treatment currently in Phase III testing. Shares of Galana are up over 233% since November.

Ahn said Galena has seen exciting and promising results from its studies so far, which have shown either a delay or prevention of cancer recurrence. He said the company has a multi-billion dollar opportunity, both for breast cancer as well as gastric cancer and as a standalone and combination treatment with other drugs.

When asked about delays in getting the Phase III stuff off the ground, Ahn said it takes time to set up the 130 hospitals in 15 countries that will be testing the drug, but the study will be fully enrolled by mid year.

Ahn also responded to critics who charge Galena is ignoring the fact that NeuVax may not help, and may even harm, some patients. He said it's totally appropriate for any new drug to have its skeptics, and that NeuVax, like every drug, has a segment of patients for which it is most effective and others where it's not effective. In Phase II testing NeuVax saw 0% cancer recurrence, and that's what the company is now testing in Phase III.

Cramer said there is a lot of research, both pro and con, regarding Galena and investors need to do their homework and be informed.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EW $82.02 0.00%
GALE $0.63 0.00%
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs